Every Semax (ACTH Fragment Peptide) Question Answered, in 17 Studies

17 referenced articles

• What Is Semax? Origin, Sequence and Neurotrophin Mechanism4 sources
• What a Fragment Keeps Decides What It Does4 sources
• What the Animal Behavioural Work Reports2 sources
• A Mechanism Layer Below Gene Expression2 sources
• What the Melanocortin Neuroprotection Literature Reports3 sources
• Where This Line of Research Started3 sources
• Semax, MT-2 and KPV Are Pieces of the Same Sequence4 sources
• Where ACTH, Alpha-MSH and Beta-Endorphin All Come From3 sources
• Semax vs Selank: How They Differ3 sources
• Semax Storage, Stability and Reconstitution2 sources
• Semax CAS Number and Chemical Identity2 sources
• Semax Regulatory Status: Registered Where, and Why It Matters4 sources
• Semax in the Published Literature4 sources
• Semax Mechanism: Neurotrophin Expression4 sources
• What Are Glyprolines? The Pro-Gly-Pro Motif Explained3 sources
• Semax Structure, Sequence and Physical Properties2 sources
• Is Semax Really an ACTH(4-10) Analogue?2 sources

Open research questions

• What is Semax?
• Is Semax really an ACTH(4-10) analogue?
• How does Semax affect BDNF?
• What are glyprolines?
• Is Semax approved in the UK?
• How does Semax differ from Selank?

Deep dive: what the Pro-Gly-Pro extension actually accomplishes

Semax is built from a four-residue fragment of ACTH with Pro-Gly-Pro appended, and that appendix does two separate jobs at once. Proline is the only proteinogenic amino acid whose side chain bonds back to its own backbone nitrogen, forming a ring that removes the amide hydrogen and locks rotation. Proteolytic enzymes generally need an extended, rotatable backbone at their active site, so bonds near proline are poor substrates for most of them — which is why proline-rich motifs recur throughout stabilised peptide design. The second job is subtractive: Pro-Gly-Pro occupies the positions where ACTH carries Arg-Trp-Gly, and those are the residues contributing to the parent hormone's adrenal-stimulating activity. One substitution therefore buys protease resistance and removes an unwanted pharmacology, which is unusually economical design.

Deep dive: the naming point worth getting right

Semax is near-universally described as an ACTH(4-10) analogue, and peer-reviewed paper titles use that phrase. Structurally it is not quite that. ACTH residues 4 to 10 are Met-Glu-His-Phe-Arg-Trp-Gly; Semax is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues match and the last three are wholly different — replacement rather than modification. PubChem, indexing by structure rather than design lineage, records it as ACTH(4-7) plus Pro-Gly-Pro. Neither name is wrong, but the loose one obscures the fact that the substituted segment is precisely the functionally consequential part.

Deep dive: reading an unevenly distributed evidence base

Semax's roughly 231 indexed records split along an unusual line. Mechanistic work — BDNF and trkB expression in rat hippocampus, transcriptomics in focal cerebral ischaemia, neurotrophin dynamics across brain regions — appears in international journals in English and can be assessed directly. Clinical work is concentrated in Russian-language publications, principally the Korsakov Journal of Neurology and Psychiatry, indexed by translated title and often without accessible English full text, much of it predating current standards for pre-registration and reporting. The honest position is that this is evidence which is difficult to verify independently, which is a different thing from evidence that is absent, and a different thing again from evidence that is established.

Handling checklist

• Store lyophilised material cold, dry and protected from light
• Expect methionine oxidation as the degradation route (+16 Da; only one Met, so not +32)
• No reducing agent needed — the sequence contains no cysteine
• Introduce diluent gently against the vial wall; swirl rather than shake
• Aliquot to avoid repeated freeze-thaw cycles
• Check whether a certificate reports net peptide content or gross salt weight

Common mistakes

Describing Semax as ACTH(4-10) without qualification

It shares only residues 4-7; Pro-Gly-Pro replaces Arg-Trp-Gly, and that replacement is the design's whole point.

Treating Russian registration as equivalent to MHRA approval

Authorisations are jurisdictional and do not transfer. Semax has never been assessed by the MHRA, EMA or FDA.

Reading a BDNF expression change as a demonstrated outcome

The studies measured gene and protein expression in rats. Expression is upstream of function and upstream again of any clinical claim.

Assuming a named receptor exists

No primary receptor has been definitively established; the literature characterises downstream effects more confidently than the initiating event.

Expecting ACTH-like adrenal effects

Semax does not stimulate adrenal steroidogenesis — the responsible residues were substituted out.